generic medication access

In the ongoing debate between commercial protectionism and the accessibility of affordable pharmaceuticals, the United States finds itself at a critical juncture. While the FDA’s stringent regulations on imported generics from countries like India are justified by health concerns, there is a growing perception that these measures increasingly serve commercial interests. Critics argue that the influence of Big Pharma has led to policies that prioritize corporate profits over consumer welfare, resulting in higher healthcare costs for Americans. This article explores the origins of these regulatory measures, the role of pharmaceutical lobbying, and the economic impacts of protectionism, calling for reforms to balance safety with affordability and accessibility.